Seung S K, Sneed P K, McDermott M W, Shu H K, Leong S P, Chang S, Petti P L, Smith V, Verhey L J, Wara W M, Phillips T L, Larson D A
Department of Radiation Oncology, University of California, San Francisco 94143-0226, USA.
Cancer J Sci Am. 1998 Mar-Apr;4(2):103-9.
To evaluate the efficacy and toxicity of gamma knife radiosurgery in the treatment of melanoma metastases to the brain.
We retrospectively reviewed 55 patients with single or multiple intracranial melanoma metastases treated at the University of California, San Francisco, with gamma knife radiosurgery from 1991 through 1995. Sixteen patients were treated with gamma knife radiosurgery for recurrence following previous radiation therapy, 11 received radiosurgery as a boost to whole-brain radiation therapy, and 28 had radiosurgery alone for initial management of brain metastases. The median minimum radiosurgery tumor dose for 140 treated lesions was 19 Gy (range, 10-22 Gy) prescribed at the 35% to 90% isodose contour (median, 50%). The median total target volume per patient was 6.1 cc (range, 0.25-28.3 cc).
With a median follow-up of 75 weeks in living patients, the median survival times were 35 weeks overall: 35 weeks for patients with solitary metastases versus 33 weeks for those with multiple metastases. A factor that was significant in univariate analysis of survival was total target volume treated. This parameter remained significant on multivariate analysis. The actuarial median freedom from progression analyzed by lesion for 113 lesions in 46 patients with imaging follow-up was 89 weeks with 6-month and 1-year actuarial freedom from progression rates of 89% (95% confidence interval, 80%-95%) and 77% (95% confidence interval, 62%-87%). In univariate analysis, improved freedom from progression was associated with smaller target volume treated, smaller maximum diameter, or higher prescribed dose. Four patients (7%) developed acute Radiation Therapy Oncology Group grade > or = 2 morbidity, and five patients (9%) developed late grade > or = 2 morbidity.
Median survival and freedom from progression in patients treated with radiosurgery for melanoma metastatic to the brain are comparable to results in published radiosurgery series of grouped histologies. For melanoma patients, total intracranial tumor volume appears to be of greater prognostic significance than the absolute number of metastases treated. We conclude that gamma knife radiosurgery is effective and should be considered among various management strategies.
评估伽玛刀放射外科治疗黑色素瘤脑转移的疗效和毒性。
我们回顾性分析了1991年至1995年在加利福尼亚大学旧金山分校接受伽玛刀放射外科治疗的55例单发或多发颅内黑色素瘤转移患者。16例患者因先前放疗后复发接受伽玛刀放射外科治疗,11例接受放射外科作为全脑放射治疗的强化治疗,28例仅接受放射外科治疗作为脑转移的初始治疗。140个治疗病灶的中位最小放射外科肿瘤剂量为19 Gy(范围10 - 22 Gy),在35%至90%等剂量曲线(中位值50%)处处方。每位患者的中位总靶体积为6.ī cc(范围0.25 - 28.3 cc)。
存活患者的中位随访时间为75周,总体中位生存时间为35周:单发转移患者为35周,多发转移患者为33周。生存单因素分析中一个显著因素是治疗的总靶体积。该参数在多因素分析中仍具有显著性。46例有影像随访的患者中113个病灶按病灶分析的无进展精算中位时间为忄9周,6个月和1年的无进展精算率分别为89%(95%可信区间80% - 95%)和77%(95%可信区间62% - 87%)。单因素分析中,更好的无进展情况与更小的治疗靶体积、更小的最大直径或更高的处方剂量相关。4例(7%)患者发生急性放射治疗肿瘤学组≥2级并发症,5例(9%)患者发生晚期≥2级并发症。
接受放射外科治疗的黑色素瘤脑转移患者的中位生存和无进展情况与已发表的按组织学分组的放射外科系列结果相当。对于黑色素瘤患者,颅内肿瘤总体积似乎比治疗的转移灶绝对数量具有更大的预后意义。我们得出结论,伽玛刀放射外科是有效的且应在各种治疗策略中予以考虑。